Recently, these two multinational pharmaceutical companies launched acquisitions, with a total amount of nearly 2 billion US dollars!

So far this year, M&A activity in the pharmaceutical industry is still very active
.
In particular, large multinational pharmaceutical companies have seen a large number of M&A transactions
in 2022.
Among them, recently, two multinational pharmaceutical companies have acquired a total of nearly 2 billion US dollars
.
1.
135 billion, Cordis announces acquisition of MedAlliance Recently, cardiovascular interventional device giant Cordis announced the acquisition of MedAlliance for a total of $1.
135 billion, including an initial investment of $35 million, an upfront closing payment of $200 million, a registration milestone payment of up to $125 million, and a performance milestone payment
of up to $775 million.
According to public information, Cordis is a company
that develops and manufactures interventional cardiovascular and endovascular technologies.
Focusing on vascular closure, radius and foot access, and intervention, Cordis has a history of more than 60 years and operates in more than 70 countries
around the world.
MedAlliance focuses on the development of advanced drug device portfolio products with breakthrough technologies, focusing on the treatment of
coronary and peripheral artery diseases.
Its product, SELUTION SLR™, is a novel rapamycin-eluting balloon platform technology
.
IT IS UNDERSTOOD THAT THE SELUTION SLR™ IS A DRUG BALLOON USING A MICRO-RESERVOIR, DESIGNED TO PROVIDE THE LONGEST AND MOST EFFECTIVE PHARMACOKINETIC DRUG COATING DEVICE ON THE MARKET, AND THE EFFECT IS COMPARABLE TO THE NEW GENERATION OF DRUG-ELUTING STENTS
.
Through the acquisition of MedAlliance, Cordis expects to provide SELUTION SLR™ (rapamycin extended-release) drug balloons
to two million patients worldwide by 2027.
The acquisition of MedAlliance is expected to close in 2023, subject to regulatory approvals and other agreed acquisition conditions
.
Eli Lilly acquires gene therapy for inner ear diseases for $610 million On October 18, Eli Lilly announced the acquisition of Akouos, a company focused on gene therapy for inner ear diseases, for $610 million to advance the first gene therapy clinical trial for deafness and expand Lilly's presence
in gene therapy.
Founded in 2016, Akoouos develops adeno-associated virus (AAV)-based gene therapies to treat diseases
including sensory deafness.
At present, Akouos is progressing faster with the AK-OTOF project, an AAV gene therapy
for the treatment of sensory hearing loss caused by a mutation in the ototitin gene (OTOF).
In addition, Akoouos has several ongoing development pipelines, including AK-CLRN1, which treats Usher syndrome type
3A caused by mutations in the CLRN1 gene.
Conclusion In general, the purpose of continuous mergers and acquisitions of large pharmaceutical companies mainly includes strengthening their R&D pipelines, investing in blockbuster drugs under research or about to be launched, complementarity of product portfolios, and synergistic economies of scale
.
Analysts believe that from the current development status of the industry, in the context of continuous changes in the pharmaceutical industry and intensifying market competition, the tide of mergers and acquisitions in the pharmaceutical industry will continue, and the total transactions of large pharmaceutical companies may exceed 1.
7 trillion US dollars
in 2022.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.